Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0081256 |
| Name | astrocytoma, IDH-mutant, grade 2 |
| Definition | An IDH-mutant anaplastic astrocytoma that is characterized by the presence of well-differentiated fibrillary glial cells diffusely infiltrating the central nervous system. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma anaplastic astrocytoma IDH-mutant anaplastic astrocytoma astrocytoma, IDH-mutant, grade 2 |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| IDH1 act mut | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH2 act mut | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH1 R132X | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH2 R172X | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH1 R132C | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH1 R132G | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH1 R132H | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH1 R132L | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH1 R132S | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH2 R172M | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH2 R172K | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH2 R172W | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH2 R172S | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| IDH2 R172G | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
| NCT06478212 | Phase Ib/II | Temozolomide + Vorasidenib | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | Recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | AUT | 2 |
| NCT06809322 | Phase III | Vorasidenib | Vorasidenib Maintenance for IDH Mutant Astrocytoma (VIGOR) | Not yet recruiting | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT | 0 |
| NCT06894979 | Phase I | AZD1390 | Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | Recruiting | USA | 0 |